Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioceres Crop Solutions (BIOX) Receivables (2017 - 2026)

Bioceres Crop Solutions' Receivables history spans 10 years, with the latest figure at $136.3 million for Q1 2026.

  • On a quarterly basis, Receivables changed N/A to $136.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $136.3 million, a N/A change, with the full-year FY2025 number at $188.5 million, down 15.83% from a year prior.
  • Receivables hit $136.3 million in Q1 2026 for Bioceres Crop Solutions, down from $188.5 million in the prior quarter.
  • Over the last five years, Receivables for BIOX hit a ceiling of $223.9 million in Q2 2024 and a floor of $115.4 million in Q2 2022.
  • Historically, Receivables has averaged $170.2 million across 5 years, with a median of $186.8 million in 2023.
  • Biggest five-year swings in Receivables: skyrocketed 61.89% in 2023 and later fell 15.83% in 2025.
  • Tracing BIOX's Receivables over 5 years: stood at $115.4 million in 2022, then skyrocketed by 61.89% to $186.8 million in 2023, then rose by 19.87% to $223.9 million in 2024, then dropped by 15.83% to $188.5 million in 2025, then dropped by 27.69% to $136.3 million in 2026.
  • Business Quant data shows Receivables for BIOX at $136.3 million in Q1 2026, $188.5 million in Q2 2025, and $223.9 million in Q2 2024.